Patents by Inventor Raymond F. Schinazi

Raymond F. Schinazi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • [5-carboxamido or 5-fluoro]-[2?,3?-unsaturated or 3?-modified]-pyrimidine nucleosides
    Patent number: 7419966
    Abstract: A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2?,3?-dideoxy-2?,3?-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3?-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5? or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: September 2, 2008
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Dennis C. Liotta
  • Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
    Patent number: 7402588
    Abstract: A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5? or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A process for the resolution of a racemic mixture of nucleoside enantiomers is also disclosed that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: July 22, 2008
    Assignee: Emory University
    Inventors: Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
  • 2?-Fluoronucleosides
    Patent number: 7307065
    Abstract: A class of 2?-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: December 11, 2007
    Assignees: Emory University, The University of Georgia Research Foundation, Inc.
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Treatment of EBV and KHSV infection
    Patent number: 7211570
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: May 1, 2007
    Assignees: Pharmasset, Inc., Emory University, Beth Israel Deaconess Medical Center
    Inventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
  • Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
    Patent number: 7160999
    Abstract: A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (?)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: January 9, 2007
    Assignee: Emory University
    Inventors: Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
  • HIV-1 mutations selected for by ?-2?,3?-didehydro-2?,3?-dideoxy-5-fluorocytidine
    Patent number: 7115584
    Abstract: The present invention discloses a method for treating HIV that includes administering ?-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using ?-D-D4FC as “salvage therapy” to patients which exhibit drug resistance to other anti-HIV agents. ?-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.
    Type: Grant
    Filed: January 23, 2003
    Date of Patent: October 3, 2006
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Jennifer L. Hammond, John W. Mellors, Dennis C. Liotta
  • Use of (R)-peniciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases
    Patent number: 7045525
    Abstract: A method of treatment of: i) HIV-1 infections in mammals, including humans; or ii) HBV infections in mammals, including humans; which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphosphate of a compound of formula (A) or a pharmaceutically acceptable salt thereof; and compounds for use in the method.
    Type: Grant
    Filed: April 23, 1996
    Date of Patent: May 16, 2006
    Assignee: Novartis AG
    Inventors: Richard Anthony Vere Hodge, Raymond F Schinazi
  • Method of treatment of viral infection including HIV using water soluble fullerenes—III
    Patent number: 6979566
    Abstract: A water soluble derivative of buckministerfullerene (C50) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.
    Type: Grant
    Filed: February 1, 2003
    Date of Patent: December 27, 2005
    Assignee: The Regents of the University of California
    Inventors: Simon H. Friedman, Raymond F. Schinazi, Fred Wudl, Craig L. Hill, Diane L. DeCamp, Rintje P. Sijbesma, George L. Kenyon
  • ?-2?- or 3?-halonucleosides
    Patent number: 6949522
    Abstract: The present invention includes compounds and compositions of ?-halonucleosides, as well as methods to treat HIV, HBV or abnormal cellular proliferation comprising administering said compounds or compositions.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: September 27, 2005
    Assignees: Pharmasset, Inc., The University of Georgia Research Foundation, Inc., Emory University
    Inventors: Michael J. Otto, Junxing Shi, Chung K. Chu, Raymond F. Schinazi, Giuseppe Gumina, Youhoon Chong, Yongseok Choi
  • Polyoxometalate compounds as antiviral agents
    Patent number: 6911470
    Abstract: Polyoxometalate compounds which exhibit anti-retroviral activity are disclosed. Compounds with anti-retroviral activity include those having the following general molecular formulas: M7PW11O39 M8SiW11O39 M9HSiW9O34 M8HPW9O34 M10(TM)4(PW9O34)2 M16(TM)4(P2W15O56)2 M14[NaP5W30O110] M12(TM)3(PW9O34)2 M6P2W18O62 wherein M is an alkali metal, NH4+ or other common monocation or soluble dication, or any combination of the above provided adequate water solubility is exhibited, or histidinium ion, argininium ion, or lysinium ion or any dication of a dipeptide or oligopeptide with 2 protonated basic amino acid residues, or any combination of these monocations or dications with each other or with any common inorganic cation, and TM is a divalent transition metal ion, such as Mn, Fe, Co, Ni, Cu and Zn.
    Type: Grant
    Filed: October 25, 1993
    Date of Patent: June 28, 2005
    Inventors: Raymond F. Schinazi, Craig L. Hill
  • 2?-fluoronucleosides
    Patent number: 6911424
    Abstract: A class of 2?-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer.
    Type: Grant
    Filed: January 30, 2002
    Date of Patent: June 28, 2005
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • ?-L-2'-deoxy-nucleosides for the treatment of HIV infection
    Patent number: 6896900
    Abstract: Compounds and pharmaceutical compositions active against HIV are provided, as is a method for the treatment of HIV infection in humans and other host animals is provided comprising administering an effective amount of a ?-L-(2? or 3?-azido)-2?,3?-dideoxy-5-fluorocytosine of the formula wherein R is H, acyl, monophosphate, diphosphate, or triphosphate, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug), and R? is H, acyl, or alkyl.
    Type: Grant
    Filed: June 18, 2002
    Date of Patent: May 24, 2005
    Assignees: Emory University, Centre National de la Recherche Scientifique, The UAB Research Foundation
    Inventors: Gilles Gosselin, Jean-Louis Imbach, Jean-Pierre Sommadossi, Raymond F. Schinazi
  • 2'-Fluoronucleosides
    Publication number: 20040254141
    Abstract: A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer.
    Type: Application
    Filed: March 8, 2004
    Publication date: December 16, 2004
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
    Publication number: 20040171124
    Abstract: A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (−)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
    Type: Application
    Filed: March 5, 2004
    Publication date: September 2, 2004
    Applicant: Emory University, Inc.
    Inventors: Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
  • [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides
    Publication number: 20040167140
    Abstract: A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2′,3′-dideoxy-2′,3′-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3′-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5′ or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: January 16, 2004
    Publication date: August 26, 2004
    Applicant: Emory University
    Inventors: Raymond F. Schinazi, Dennis C. Liotts
  • HIV-1 mutations selected for by beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine
    Publication number: 20040082552
    Abstract: The present invention discloses a method for treating HIV that includes administering &mgr;-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using &bgr;-D-D4FC as “salvage therapy” to patients which exhibit drug resistance to other anti-HIV agents. &bgr;-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.
    Type: Application
    Filed: January 23, 2003
    Publication date: April 29, 2004
    Inventors: Raymond F. Schinazi, Jennifer L. Hammond, John W. Mellors, Dennis C. Liotta
  • 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
    Publication number: 20040067877
    Abstract: A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a &bgr;-L- or &bgr;-D-2′,3′-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Application
    Filed: August 1, 2003
    Publication date: April 8, 2004
    Inventors: Raymond F. Schinazi, Robert Striker, Junxing Shi
  • Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
    Patent number: 6703396
    Abstract: A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (−)-2-hydroxymethyl-5-(5-flurocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
    Type: Grant
    Filed: March 13, 1995
    Date of Patent: March 9, 2004
    Assignee: Emory University
    Inventors: Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
  • Method of treatment of viral infection including HIV using water soluble fullerenes - III
    Publication number: 20040044062
    Abstract: A water soluble derivative of buckministerfullerene (C50) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.
    Type: Application
    Filed: February 1, 2003
    Publication date: March 4, 2004
    Inventors: Simon H. Friedman, Raymond F. Schinazi, Fred Wudl, Craig L. Hill, Diane L. DeCamp, Rintje P. Sijbesma, George L. Kenyon
  • Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
    Publication number: 20040038350
    Abstract: A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (−)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
    Type: Application
    Filed: August 20, 2003
    Publication date: February 26, 2004
    Inventors: Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi